Kannalife Sciences, Inc.

Kannalife Sciences, Inc. is a biopharmaceutical company based in Doylestown, Pennsylvania, that specializes in the research and development of synthetic, cannabidiol-inspired therapeutics. A subsidiary of Neuropathix, Inc., the company focuses on creating small molecule drug candidates designed to address neuroinflammation, neuropathic pain, and neurodegenerative diseases. By utilizing proprietary technology to synthesize novel compounds, such as its lead candidate KLS-13019, Kannalife aims to optimize bioavailability and therapeutic potency to treat conditions including Parkinson’s disease, hepatic encephalopathy, and chemotherapy-induced peripheral neuropathy.

These therapeutic efforts aim to provide patients with alternatives to traditional treatments, including non-opioid options for pain management and solutions for complex neurological disorders. The company’s work is supported by strategic grants from organizations such as the National Institutes of Health and The Michael J. Fox Foundation, alongside partnerships with research institutions and pharmaceutical service providers. Through its commitment to rigorous pre-clinical development and a portfolio of patented molecular entities, Kannalife seeks to improve cellular health and address significant unmet medical needs in neurological health.